Cargando…

Up-regulation of GSTT1 in serous ovarian cancer associated with resistance to TAXOL / carboplatin

Serous ovarian cancer (SOC) is the most common women cancer and the leading cause of cancer-related mortality among the gynaecological malignancies. Although effective chemotherapeutics combined with surgery are developed for the treatment, the five-year survival rate is unsatisfactory due to chemor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jing, Xie, Suhong, Zhou, Lei, Tang, Xiaoyu, Guan, Xiaolin, Deng, Minjie, Zheng, Hui, Wang, Yanchun, Lu, Renquan, Guo, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447655/ https://www.ncbi.nlm.nih.gov/pubmed/34535163 http://dx.doi.org/10.1186/s13048-021-00873-2

Ejemplares similares

Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin
por: Deng, Minjie, et al.
Publicado: (2019)

MUS81 Participates in the Progression of Serous Ovarian Cancer Associated With Dysfunctional DNA Repair System
por: Lu, Renquan, et al.
Publicado: (2019)

Human leukocyte antigen-E alleles and expression in patients with serous ovarian cancer
por: Zheng, Hui, et al.
Publicado: (2015)

IFN-γ in ovarian tumor microenvironment upregulates HLA-E expression and predicts a poor prognosis
por: Zheng, Hui, et al.
Publicado: (2023)

TTK is a potential therapeutic target for cisplatin-resistant ovarian cancer
por: Liu, Yixuan, et al.
Publicado: (2021)

High expression of RIPK2 is associated with Taxol resistance in serous ovarian cancer
por: Shen, Yuqing, et al.
Publicado: (2022)

Transcriptome-based signature predicts the effect of taxol in serous ovarian cancer
por: Hou, Shunyu, et al.
Publicado: (2018)

TPX2 promotes ovarian tumorigenesis by interacting with Lamin A/C and affecting its stability
por: Meng, Xin, et al.
Publicado: (2023)

Identification of the key genes associated with chemotherapy sensitivity in ovarian cancer patients
por: Zheng, Hui, et al.
Publicado: (2020)

Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers
por: Neal, Adam, et al.
Publicado: (2021)

VHL regulates the sensitivity of clear cell renal cell carcinoma to SIRT4-mediated metabolic stress via HIF-1α/HO-1 pathway
por: Tong, Ying, et al.
Publicado: (2021)

Primary high-grade serous ovarian cancer cells are sensitive to senescence induced by carboplatin and paclitaxel in vitro
por: Uruski, Paweł, et al.
Publicado: (2021)

CALD1 is a prognostic biomarker and correlated with immune infiltrates in gastric cancers
por: Liu, Yixuan, et al.
Publicado: (2021)

Serology-Based Model for Personalized Epithelial Ovarian Cancer Risk Evaluation
por: Yan, Tianqing, et al.
Publicado: (2022)

RASSF1A and the Taxol Response in Ovarian Cancer
por: Kassler, Susannah, et al.
Publicado: (2012)

Leptin contributes to the taxol chemoresistance in epithelial ovarian cancer
por: Gu, Fei, et al.
Publicado: (2019)

MYSM1 induces apoptosis and sensitizes TNBC cells to cisplatin via RSK3–phospho-BAD pathway
por: Guan, Xiaolin, et al.
Publicado: (2022)

Effects of combining Taxol and cyclooxygenase inhibitors on the angiogenesis and apoptosis in human ovarian cancer xenografts
por: LI, WEI, et al.
Publicado: (2013)

A Risk of Venous Thromboembolism Algorithm as a Predictor of Venous Thromboembolism in Patients with Colorectal Cancer
por: Chen, Ying, et al.
Publicado: (2021)

Differentially Expressed Genes in Clear Cell Renal Cell Carcinoma as a Potential Marker for Prognostic and Immune Signatures
por: Tong, Ying, et al.
Publicado: (2021)

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer
por: Huang, Chen-Yu, et al.
Publicado: (2020)

Taxol: an important new drug in the management of epithelial ovarian cancer.
por: Markman, M.
Publicado: (1991)

Platinum-Taxol non-cross resistance in epithelial ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1995)

Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis
por: Zhan, Shi-Jie, et al.
Publicado: (2018)

Association of maternal CNVs in GSTT1/GSTT2 with smoking, preterm delivery, and low birth weight
por: Zheng, Xiaojing, et al.
Publicado: (2013)

Capable Infection of Hepatitis B Virus in Diffuse Large B-cell Lymphoma
por: Wang, Yanchun, et al.
Publicado: (2018)

Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.
por: Gore, M. E., et al.
Publicado: (1995)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
por: Tan, Xiangbin, et al.
Publicado: (2023)

Establishment of a detection assay for DNA endonuclease activity and its application in the screening and prognosis of malignant lymphoma
por: Lu, Renquan, et al.
Publicado: (2018)

Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk
por: Lampert, Erika J., et al.
Publicado: (2019)

Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma
por: Burkett, Wesley C., et al.
Publicado: (2023)

MUS81 Inhibition Increases the Sensitivity to Therapy Effect in Epithelial Ovarian Cancer via Regulating CyclinB Pathway
por: Zhong, Ailing, et al.
Publicado: (2019)

Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro.
por: Jekunen, A. P., et al.
Publicado: (1994)

Effect of taxol on the expression of FoxM1 ovarian cancer-associated gene
por: LIU, ZENG, et al.
Publicado: (2016)

Optimization of Taxol Extraction Process Using Response Surface Methodology and Investigation of Temporal and Spatial Distribution of Taxol in Taxus mairei
por: Li, Lingyu, et al.
Publicado: (2021)

Paclitaxel plus Carboplatin Chemotherapy for Primary Peritoneal Carcinoma: A Study of 22 Cases and Comparison with Stage III–IV Ovarian Serous Carcinoma
por: Kawaguchi, R., et al.
Publicado: (2012)

STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer
por: Ghaffari, Abdi, et al.
Publicado: (2018)

Sensitization of Carboplatinum- and Taxol-Resistant High-Grade Serous Ovarian Cancer Cells Carrying p53, BRCA1/2 Mutations by Emblica officinalis (Amla) via Multiple Targets
por: De, Alok, et al.
Publicado: (2020)

Cisplatin/carboplatin cross-resistance in ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1989)

Taxol binds to cellular microtubules
Publicado: (1982)

Cannot write session to /tmp/vufind_sessions/sess_29t7dmqfeipua8spqd9g65trle